The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
NCCN guidelines updated to include a ctDNA-MRD testing recommendation for B-cell lymphoma
On January 10, 2025, it was announced that the National Comprehensive Cancer Network (NCCN) has updated its clinical practice guidelines for diffuse large B-cell lymphoma (DLBCL) to include circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD).1
The guidelines now recommend ctDNA-MRD testing as an alternative to biopsy for evaluating PET-positive results at the end of first-line therapy in DLBCL. These updates will aid in improving identification of patients in need of additional therapy.1
The inclusion of ctDNA testing aims to reduce unnecessary procedures and treatment burdens for patients, addressing challenges like false positives in PET scans and the need for invasive biopsies.1
This is the first time ctDNA-MRD testing has been included in these guidelines, marking a significant advancement in lymphoma patient care.1
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
